- Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024
- Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
- Olink publishes 2023 annual report
- Olink reports fourth quarter and full year 2023 financial results
- Notice to attend the Annual General Meeting of Olink Holding AB (publ)
- Olink announces change of date for Annual General Meeting
- Olink reports third quarter 2023 financial results
- Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics
- Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
More ▼
Key statistics
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 124.34m |
Free float | 39.58m |
P/E (TTM) | -- |
Market cap | 2.88bn USD |
EPS (TTM) | -0.2547 USD |
--
More ▼